Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012. ,
Treatment paradigms for patients with metastatic nonsmall-cell lung cancer: first-, second-, and third-line, Curr Oncol, vol.19, issue.1, pp.52-58, 2012. ,
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, vol.26, issue.21, pp.3543-51, 2008. ,
,
, Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer, N Eng J Med, vol.346, issue.2, pp.92-100, 2002.
,
Innate and adaptive immune cells in the tumor microenvironment, Nat Immunol, vol.14, issue.10, pp.1014-1036, 2013. ,
,
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, vol.331, issue.6024, pp.1565-70, 2011. ,
Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-999, 2002. ,
Natural innate and adaptive immunity to cancer, Ann Rev Immunol, vol.29, pp.235-71, 2011. ,
,
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-64, 2012. ,
,
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Eng J Med, vol.373, issue.17, pp.1627-1666, 2015. ,
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Eng J Med, vol.373, issue.2, pp.123-158, 2015. ,
Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, vol.27, issue.4, pp.450-61, 2015. ,
B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction, Cancer J, vol.20, issue.4, pp.281-290, 2014. ,
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Eng J Med, vol.366, issue.26, pp.2455-65, 2012. ,
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Eng J Med, vol.366, issue.26, pp.2443-54, 2012. ,
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-570, 2014. ,
,
Immunogenic cell death in cancer and infectious disease, Nat Rev Immunol, vol.17, issue.2, pp.97-111, 2017. ,
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials, Euro J Cancer, vol.46, issue.4, pp.735-778, 2010. ,
,
RECIST 1.1-Update and clarification: From the RECIST committee, Euro J Cancer, vol.62, pp.132-139, 2016. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 2016. ,
Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012. ,
Immunotherapy revolutionises non-smallcell lung cancer therapy: results, perspectives and new challenges, Eur J Cancer Oxf Engl, vol.78, pp.16-23, 1990. ,
Immune checkpoint blockade: a new era for non-small cell lung cancer, Curr Oncol Rep, vol.18, issue.9, p.59, 2016. ,
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, vol.373, issue.17, pp.1627-1639, 2015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-1550, 2016. ,
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response, Biomark Res, vol.5, p.12, 2017. ,
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?, J Immunother Cancer, vol.4, p.48, 2016. ,
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, vol.10, pp.1823-1833, 2016. ,
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, pp.5064-5074, 2014. ,
Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, vol.372, issue.21, pp.2018-2028, 2015. ,
Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors, Front Immunol, vol.9, p.1310, 2018. ,
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res Off J Am Assoc Cancer Res, vol.22, issue.22, pp.5487-5496, 2016. ,
Lung cancer epidemiology: contemporary and future challenges worldwide, Ann Transl Med, vol.4, issue.8, 2016. ,
Stromal CD8 + T-cell density-a promising supplement to TNM staging in non-small cell lung cancer, Clin. Cancer Res, vol.21, pp.2635-2643, 2015. ,
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type, Cancer Epidemiol. Prev. Biomark, vol.23, pp.2965-2970, 2014. ,
Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets, vol.15, pp.452-62, 2015. ,
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med, vol.375, pp.1823-1833, 2016. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1540-1550, 2016. ,
Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med, vol.372, 2015. ,
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med, vol.373, pp.1627-1639, 2015. ,
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med, vol.373, pp.123-135, 2015. ,
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer, Cancer Cell, vol.33, pp.843-852, 2018. ,
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, vol.387, pp.1837-1846, 2016. ,
Nivolumab versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med, vol.373, pp.1803-1813, 2015. ,
Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med, pp.711-723, 2010. ,
First-Line nivolumab in stage IV or recurrent non-small-cell lung cancer, N. Engl. J. Med, vol.376, pp.2415-2426, 2017. ,
PD-1/PD-L1 inhibitors, Curr. Opin. Pharmacol, vol.23, pp.32-38, 2015. ,
IFN-?-related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Invest, vol.127, pp.2930-2940, 2017. ,
Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx analysis system, J. Clin. Oncol, vol.34, issue.15_suppl, pp.3034-3034, 2016. ,
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment, Int Immunopharmacol, vol.46, pp.210-219, 2017. ,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-571, 2014. ,
Classifying cancers based on T-cell infiltration and PD-L1, Cancer Res, vol.75, pp.2139-2145, 2015. ,
TCGA2STAT: simple TCGA data access for integrated statistical analysis in R, Bioinformatics, vol.32, pp.952-954, 2016. ,
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas, Mod. Pathol, vol.29, pp.1165-1172, 2016. ,
QuPath: open source software for digital pathology image analysis. bioRxiv. 6 mars, p.99796, 2017. ,
Near-optimal probabilistic RNAseq quantification, Nat. Biotechnol, vol.34, p.525, 2016. ,
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, vol.15, p.550, 2014. ,
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool, BMC Bioinform, vol.14, p.128, 2013. ,
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update, Nucleic Acids Res, vol.44, pp.90-97, 2016. ,
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, vol.45, pp.228-247, 2009. ,
Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization, PLOS ONE, vol.7, p.51862, 2012. ,
Immune-related gene expression profiling after pd-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma, Cancer Res, vol.77, pp.3540-3550, 2017. ,
Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non?small cell lung cancer patients receiving concurrent chemoradiotherapy, Eur. J. Cancer, vol.55, pp.7-14, 2016. ,
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma, OncoTargets Ther, vol.12, pp.567-73 ,
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-followup study, Tumori, vol.98, pp.751-755, 2012. ,
, Prognostic and predictive role of CD8 and PD-L1 determination in lung
,
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med Oncol, vol.28, pp.682-688, 2011. ,
PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups, PLOS ONE, vol.10, p.136023, 2015. ,
Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung, Clin. Lung Cancer, vol.14, pp.157-163, 2013. ,
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis, Sci. Rep, vol.7, p.10255, 2017. ,
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer, Clin. Cancer Res, vol.14, pp.5220-5227, 2008. ,
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Ann. Oncol, vol.27, pp.147-153, 2016. ,
Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays: impact of the architecture pattern and the number of cores, Am. J. Surg. Pathol, vol.42, p.687, 2018. ,
PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project, J. Thorac. Oncol, vol.12, pp.208-222, 2017. ,
1296O Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L + NSCLC: results from the randomized OAK study, Disponible sur, vol.28, 2017. ,
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression, Clin. Cancer Res, vol.10, pp.5094-5100, 2004. ,
Low PD-1 expression in cytotoxic CD8+ tumor infiltrating lymphocytes confers an immune privileged tissue microenvironment in NSCLC with a prognostic and predictive value, Clin. Cancer Res, vol.2156, p.2017, 2017. ,
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, vol.545, pp.60-65, 2017. ,
PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med, vol.372, pp.2509-2520, 2015. ,
Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012. ,
Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges, Eur J Cancer Oxf Engl, vol.78, pp.16-23, 1990. ,
Immune checkpoint blockade: a new era for non-small cell lung cancer, Curr Oncol Rep, vol.18, pp.59-63, 2016. ,
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, vol.373, pp.1627-1666, 2015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-50, 2016. ,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet Lond Engl, vol.389, pp.255-65, 2017. ,
Pembrolizumab for the treatment of non-small cell lung cancer, Expert Opin Biol Ther, vol.16, pp.397-406, 2016. ,
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response, Biomark Res, vol.5, pp.12-20, 2017. ,
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?, J Immunother Cancer, vol.4, pp.48-54, 2016. ,
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res, vol.20, pp.5064-74, 2014. ,
Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, vol.372, pp.2018-2046, 2015. ,
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, vol.16, pp.257-65, 2015. ,
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet Lond Engl, vol.387, pp.1837-1883, 2016. ,
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, pp.124-132, 2015. ,
Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing, J Clin Oncol, vol.36, pp.633-674, 2018. ,
Firstline nivolumab in stage IV or recurrent non-small-cell lung cancer, N Engl J Med, vol.376, pp.2415-2441, 2017. ,
RECIST 1.1-Update and clarification: frrom the RECIST committee, Eur J Cancer Oxf Engl, vol.62, pp.132-139, 1990. ,
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization, PloS One, vol.7, p.51862, 2012. ,
Regularization paths for generalized linear models via coordinate descent, J Stat Softw, vol.33, pp.1-22, 2010. ,
Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach, Stat Med, vol.34, pp.685-703, 2015. ,
Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability, J Clin Oncol, vol.35, pp.1096-1096, 2017. ,
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy, Genome Biol, vol.16, pp.64-70, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01149718
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice, Clin Cancer Res, vol.19, pp.393-403, 2013. ,
Loss of PTEN promotes resistance to T cell-mediated immunotherapy, Cancer Discov, vol.6, pp.202-218, 2016. ,
Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer, Cancer Cell, vol.33, pp.843-852, 2018. ,
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multiomic analysis, PLoS Med, vol.14, p.1002309, 2017. ,
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, Science, vol.359, pp.801-807, 2018. ,
Tracking the evolution of non-small-cell lung cancer, N Engl J Med, vol.376, pp.2109-2130, 2017. ,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-71, 2014. ,
,
A method and server for predicting damaging missense mutations, Nat. Methods, vol.7, pp.248-249, 2010. ,
Predicting functional effect of human missense mutations using PolyPhen-2, Curr Protoc Hum Genet Chapter, p.20, 2013. ,
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer, Ann. Oncol, vol.25, pp.1750-1755, 2014. ,
Models, mechanisms and clinical evidence for cancer dormancy, Nat. Rev. Cancer, vol.7, pp.834-846, 2007. ,
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, vol.114, pp.1537-1544, 2009. ,
Signatures of mutational processes in human cancer, Nature, vol.500, pp.415-421, 2013. ,
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer, Cancer Discov, vol.7, pp.264-276, 2017. ,
Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer : an individual patient data meta-analysis, J. Natl. Cancer Inst, vol.99, pp.847-857, 2007. ,
The paradox of Th17 cell functions in tumor immunity, Cell. Immunol, vol.322, pp.15-25, 2017. ,
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations, J Immunother Cancer, vol.7, p.91, 2019. ,
Gene ontology : tool for the unification of biology. The Gene Ontology Consortium, Nat. Genet, vol.25, pp.25-29, 2000. ,
IFN-?-related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Invest, vol.127, pp.2930-2940, 2017. ,
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology, Ann Pharmacother, vol.49, pp.907-937, 2015. ,
Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, vol.439, pp.682-687, 2006. ,
Routine molecular profiling of patients with advanced non-small-cell lung cancer : results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, vol.387, p.151, 2016. ,
, Oral, Head and Neck Oncology and Reconstructive Surgery, pp.314-340, 2018.
,
Accurate whole human genome sequencing using reversible terminator chemistry, Nature, vol.456, pp.53-59, 2008. ,
Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Partie 1 -Tumeur solides, 2013. ,
A review of cellular senescence : friend or foe of tumorigenesis ?, Med Sci, vol.25, pp.153-160, 2009. ,
An estimate of cancers attributable to occupational exposures in France, J. Occup. Environ. Med, vol.52, pp.399-406, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-01260430
MiXCR : software for comprehensive adaptive immunity profiling, Nat. Methods, vol.12, pp.380-381, 2015. ,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.373, pp.1627-1639, 2015. ,
Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers : a quantitative review to, Ann. Oncol, vol.18, pp.431-446, 2005. ,
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med, vol.366, pp.2455-2465, 2012. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.373, pp.123-135, 2015. ,
Abstract CT077 : Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC) : Clinical characteristics of long-term survivors, Cancer Research, vol.77, pp.77-077, 2017. ,
Global cancer statistics 2018 : GLOBO-CAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, vol.68, pp.394-424, 2018. ,
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth, Nat. Med, vol.19, pp.57-64, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00919371
Trial Watch : Immunomodulatory monoclonal antibodies for oncological indications, Oncoimmunology, vol.4, p.1008814, 2015. ,
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity, vol.27, pp.111-122, 2007. ,
Cellular senescence : when bad things happen to good cells, Nat. Rev. Mol. Cell Biol, vol.8, pp.729-740, 2007. ,
Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information, Bioinformatics, vol.22, p.152, 2006. ,
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1) : Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers, PLoS ONE, vol.10, p.130142, 2015. ,
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.376, pp.2415-2426, 2017. ,
Oncology meets immunology : the cancer-immunity cycle, Immunity, vol.39, pp.1-10, 2013. ,
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer : a 5-year-follow-up study, Tumori, vol.98, pp.751-755, 2012. ,
Epidémiologie du cancer du poumon en France : incidence, mortalité et survie (tendance et situation actuelle), Revue des Maladies Respiratoires Actualités, vol.8, pp.308-318, 2016. ,
Survie des personnes atteintes de cancer en France métropolitaine, 1989-2013. Partie 1 -Tumeurs solides, 2016. ,
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity, Nat. Med, vol.9, pp.562-567, 2003. ,
A DNA damage checkpoint response in telomere-initiated senescence, Nature, vol.426, pp.194-198, 2003. ,
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression, Nature, vol.443, pp.350-354, 2006. ,
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer, J. Exp. Med, vol.208, pp.469-478, 2011. ,
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire, Nat. Biotechnol, vol.31, pp.166-169, 2013. ,
,
, Rev Mal Respir, vol.33, pp.444-459, 2016.
Medical follow-up of workers exposed to lung carcinogens : French evidence-based and pragmatic recommendations, BMC Public Health, vol.17, p.191, 2017. ,
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy : a prognostic score from individual data of nine randomised trials, Eur. J. Cancer, vol.46, pp.735-743, 2010. ,
Lung cancer and other causes of death in relation to smoking ; a second report on the mortality of British doctors, Br Med J, vol.2, pp.1071-1081, 1956. ,
Mortality in relation to smoking : 50 years' observations on male British doctors, BMJ, vol.328, p.1519, 2004. ,
Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion, Nat. Med, vol.8, pp.793-800, 2002. ,
Cancer immunoediting : from immunosurveillance to tumor escape, Nat. Immunol, vol.3, pp.991-998, 2002. ,
The three Es of cancer immunoediting, Annu. Rev. Immunol, vol.22, pp.329-360, 2004. ,
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR) : a multicentre, open-label, phase 2 randomised controlled trial, Lancet, vol.387, pp.1837-1846, 2016. ,
CD14(+)S100A9(+) monocytic myeloidderived suppressor cells and their clinical relevance in non-small cell lung cancer, Am. J. Respir. Crit. Care Med, vol.186, pp.1025-1036, 2012. ,
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio : prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann. Oncol, vol.29, p.524, 2018. ,
flowClean : Automated identification and removal of fluorescence anomalies in flow cytometry data, Cytometry A, vol.89, pp.461-471, 2016. ,
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med, vol.192, pp.1027-1034, 2000. ,
Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays : Impact of the Architecture Pattern and the Number of Cores, Am. J. Surg. Pathol, vol.42, pp.687-694, 2018. ,
Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol, vol.17, pp.97-111, 2017. ,
Tobacco smoking and cancer : a metaanalysis, Int. J. Cancer, vol.122, pp.155-164, 2008. ,
Immunogenic versus tolerogenic phagocytosis during anticancer therapy : mechanisms and clinical translation, Cell Death Differ, vol.23, pp.938-951, 2016. ,
Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med, vol.372, pp.2018-2028, 2015. ,
Cytokines prevent tumors via a cell senescence mechanism ,
, Med Sci, vol.25, pp.138-140, 2009.
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, Nature, vol.552, pp.116-120, 2017. ,
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer, J. Clin. Oncol, vol.33, 2004. ,
, First-line nivolumab
, ONO-4538) monotherapy in advanced NSCLC : Safety, efficacy, and correlation of outcomes with PD-L1 status, BMS-936558, vol.32, pp.8024-8024, 2014.
Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden, Occup Environ Med, vol.73, pp.290-299, 2016. ,
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, vol.419, pp.734-738, 2002. ,
The accumulated evidence on lung cancer and environmental tobacco smoke, BMJ, vol.315, p.154, 1997. ,
Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy, Cancer Genet, vol.206, pp.420-431, 2013. ,
flowCore : a Bioconductor package for high throughput flow cytometry, BMC Bioinformatics, vol.10, pp.1471-2105, 2009. ,
URL : https://hal.archives-ouvertes.fr/inria-00426746
Molecular pathways : the immunogenic effects of platinum-based chemotherapeutics, Clin. Cancer Res, vol.20, pp.2831-2837, 2014. ,
The carcinogenicity of metals in humans, Cancer Causes Control, vol.8, pp.371-385, 1997. ,
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer, Cancer Cell, vol.33, pp.853-861, 2018. ,
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer, Cancer Cell, vol.33, pp.843-852, 2018. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial, Lancet, vol.387, pp.1540-1550, 2016. ,
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) : 4-year outcomes of a multicentre, randomised, phase 3 trial, Lancet Oncol, vol.19, pp.1480-1492, 2018. ,
High-throughput pairing of T cell receptor ? and ? sequences, Sci Transl Med, vol.7, pp.301-131, 2015. ,
Increased CD14(+)HLA-DR (-/low) myeloidderived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients, Cancer Immunol. Immunother, vol.62, pp.1439-1451, 2013. ,
pVAC-Seq : A genome-guided in silico approach to identifying tumor neoantigens, Genome Med, vol.8, p.11, 2016. ,
Monographs on the Evaluation of Carcinogenic Risks to Humans. Tobacco smole and involuntary smoking, vol.83, pp.51-1187, 2004. ,
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances : a potential issue for anti-PD-L1 therapeutic strategies, Ann. Oncol, vol.27, pp.147-153, 2016. ,
Cytolytic T cell reactivity against melanomaassociated differentiation antigens in peripheral blood of melanoma patients and healthy individuals, Melanoma Res, vol.6, pp.419-425, 1996. ,
Tracking the Evolution of Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.376, pp.2109-2121, 2017. ,
Erojection de l'incidence et de la mortalité par cancer en France métropolitaine en 2017. Rapport technique, Santé publique France, vol.122, p.p, 2017. ,
Polarized immune responses differentially regulate cancer development, Immunol. Rev, vol.222, pp.145-154, 2008. ,
Epidermal growth factor receptor mutations in patients with non-small cell lung cancer, Cancer Res, vol.65, p.155, 2005. ,
Metabolite and Microbiome Interplay in Cancer Immunotherapy, Cancer Res, vol.76, pp.6146-6152, 2016. ,
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J. Clin. Oncol, vol.22, pp.2184-2191, 2004. ,
KEGG : kyoto encyclopedia of genes and genomes, Nucleic Acids Res, vol.28, pp.27-30, 2000. ,
Immunology's foundation : the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff, Nat. Immunol, vol.9, pp.705-712, 2008. ,
Immune Checkpoint Modulators : An Emerging Antiglioma Armamentarium, J Immunol Res, p.4683607, 2016. ,
Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma, J. Invest. Dermatol, vol.137, pp.1740-1748, 2017. ,
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer, Nat. Med, vol.24, pp.1449-1458, 2018. ,
A general framework for estimating the relative pathogenicity of human genetic variants, Nat. Genet, vol.46, pp.310-315, 2014. ,
Adaptive immunity maintains occult cancer in an equilibrium state, Nature, vol.450, pp.903-907, 2007. ,
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1, J. Exp. Med, vol.206, pp.1327-1337, 2009. ,
Senescence-messaging secretome : SMS-ing cellular stress, Nat. Rev. Cancer, vol.9, pp.81-94, 2009. ,
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, vol.357, pp.409-413, 2017. ,
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N. Engl. J. Med, vol.372, pp.2509-2520, 2015. ,
Radon, smoking and lung cancer risk : results of a joint analysis of three European case-control studies among uranium miners, Radiat. Res, vol.176, pp.375-387, 2011. ,
Comparison of next-generation sequencing systems, J. Biomed. Biotechnol, vol.2012, p.251364, 2012. ,
The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution : focus on China, Chin J Cancer, vol.33, pp.189-196, 2014. ,
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study : results of an exploratory analysis, J Thorac Oncol, vol.7, pp.1707-1712, 2012. ,
Intrinsic tumour suppression, Nature, vol.432, p.156, 2004. ,
Radon and lung cancer risk : a joint analysis of 11 underground miners studies, National Institutes of Health, 1994. ,
NetMHC-3.0 : accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11, Nucleic Acids Res, vol.36, pp.509-512, 2008. ,
The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis : some chemotherapeutical drugs may finally work through immune response, Oncotarget, vol.7, pp.29794-29803, 2016. ,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med, vol.350, pp.2129-2139, 2004. ,
Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR, N. Engl. J. Med, vol.362, pp.2380-2388, 2010. ,
Risk factors for lung cancer worldwide, Eur. Respir. J, vol.48, pp.889-902, 2016. ,
Cancer-related inflammation, Nature, vol.454, pp.436-444, 2008. ,
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients, Oncoimmunology, vol.1, pp.432-440, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00724448
Correction : Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice : a nationwide French study, Eur. J. Hum. Genet, vol.26, pp.1396-1397, 2018. ,
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, Clin. Cancer Res, vol.22, pp.2908-2918, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01409624
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress, Oncogene, vol.30, pp.1147-1158, 2011. ,
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy, Blood Adv, vol.2, pp.335-346, 2018. ,
Research Techniques Made Simple : High-Throughput Sequencing of the T-Cell Receptor, J. Invest. Dermatol, vol.137, pp.131-138, 2017. ,
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting, Nature, vol.482, pp.400-404, 2012. ,
Next-generation sequencing for cancer diagnostics : a practical perspective, Clin Biochem Rev, vol.32, pp.177-195, 2011. ,
Emerging technologies in DNA sequencing, Genome Res, vol.15, pp.1767-1776, 2005. ,
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors, Nat. Genet, vol.50, pp.1271-1281, 2018. ,
New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape, Curr. Opin. Immunol, vol.27, pp.16-25, 2014. ,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N. Engl. J. Med, vol.361, p.157, 2009. ,
DNA Damage and Repair Biomarkers of Immunotherapy Response, Cancer Discov, vol.7, pp.675-693, 2017. ,
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med. Oncol, vol.28, pp.682-688, 2011. ,
SIFT : Predicting amino acid changes that affect protein function, Nucleic Acids Res, vol.31, pp.3812-3814, 2003. ,
Molecular pathways : coexpression of immune checkpoint molecules : signaling pathways and implications for cancer immunotherapy, Clin. Cancer Res, vol.19, pp.4917-4924, 2013. ,
The Health Consequences of Smoking : 50 Years of Progress. A Report of the Surgeon General, Centers for Disease Control and Prevention, 2014. ,
Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada, Am. J. Respir. Crit. Care Med, vol.183, pp.941-948, 2011. ,
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma, Clin. Cancer Res, vol.23, pp.5187-5201, 2017. ,
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer : A Phase II Global Study, J. Clin. Oncol, vol.34, pp.661-668, 2016. ,
EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy, Science, vol.304, pp.1497-1500, 2004. ,
Next generation sequencing in cancer : opportunities and challenges for precision cancer medicine. Scand, J. Clin. Lab. Invest. Suppl, vol.245, pp.84-91, 2016. ,
The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, vol.12, pp.252-264, 2012. ,
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol. Cell. Biol, vol.25, pp.9543-9553, 2005. ,
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy, Immunity, vol.44, pp.343-354, 2016. ,
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma, J Immunother Cancer, vol.3, p.23, 2015. ,
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based ? A meta-analysis of phase III randomized trials, Lung Cancer, vol.51, pp.335-345, 2006. ,
Air pollution and lung cancer incidence in 17 European cohorts : prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE), Lancet Oncol, vol.14, pp.813-822, 2013. ,
Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo, J. Immunol, vol.164, pp.2619-2628, 2000. ,
,
, Bull Cancer, vol.104, pp.962-970, 2017.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.375, pp.1823-1833, 2016. ,
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer : AVAil, J. Clin. Oncol, vol.27, pp.1227-1234, 2009. ,
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab, Cell, vol.171, pp.934-949, 2017. ,
Tumor immunotherapy directed at PD-1, N. Engl. J. Med, vol.366, pp.2517-2519, 2012. ,
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing, J. Clin. Oncol, vol.36, pp.633-641, 2018. ,
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, pp.124-128, 2015. ,
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063) : a phase 2, single-arm trial, Lancet Oncol, vol.16, pp.257-265, 2015. ,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-246, 2012. ,
DeconstructSigs : delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution, Genome Biol, vol.17, p.31, 2016. ,
Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers : an updated systematic review and a metaanalysis to, Arch. Toxicol, vol.88, pp.1479-1490, 2014. ,
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science, vol.359, pp.91-97, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02126484
Translating genomics for precision cancer medicine, Annu Rev Genomics Hum Genet, vol.15, pp.395-415, 2014. ,
CD28 and CTLA-4 coreceptor expression and signal transduction, Immunol. Rev, vol.229, pp.12-26, 2009. ,
Long read sequencing reveals a novel class of structural aberrations in cancers : identification and characterization of cancerous local amplifications, 2019. ,
Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat. Genet, vol.51, pp.202-206, 2019. ,
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N. Engl. J. Med, vol.346, pp.92-98, 2002. ,
Cancer immunoediting : integrating immunity's roles in cancer suppression and promotion, Science, vol.331, p.159, 2011. ,
Neoantigens in cancer immunotherapy, Science, vol.348, pp.69-74, 2015. ,
RECIST 1.1-Update and clarification : From the RECIST committee, Eur. J. Cancer, vol.62, pp.132-137, 2016. ,
Systematic review and quantification of respiratory cancer risk for occupational exposure to hexavalent chromium, Int Arch Occup Environ Health, vol.86, pp.943-955, 2013. ,
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+, Prostate, vol.69, pp.1694-1703, 2009. ,
The future of immune checkpoint therapy, Science, vol.348, pp.56-61, 2015. ,
Ceritinib in ALK-rearranged non-small-cell lung cancer, N. Engl. J. Med, vol.370, pp.1189-1197, 2014. ,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N. Engl. J. Med, vol.368, pp.2385-2394, 2013. ,
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement : a retrospective analysis, Lancet Oncol, vol.12, pp.1004-1012, 2011. ,
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer, Clin. Cancer Res, vol.14, pp.5220-5227, 2008. ,
Intron retention is a source of neoepitopes in cancer, Nat. Biotechnol, vol.36, pp.1056-1058, 2018. ,
Cancer immunosurveillance and immunoediting : the roles of immunity in suppressing tumor development and shaping tumor immunogenicity, Adv. Immunol, vol.90, pp.1-50, 2006. ,
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer : An exploratory multiomic analysis, PLoS Med, vol.14, p.1002309, 2017. ,
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N. Engl. J. Med, vol.378, pp.2288-2301, 2018. ,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, vol.448, pp.561-566, 2007. ,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N. Engl. J. Med, vol.371, pp.2167-2177, 2014. ,
Immune checkpoint modulation for non-small cell lung cancer, Clin. Cancer Res, vol.21, pp.2256-2262, 2015. ,
Decisions about dendritic cells : past, present, and future, Annu. Rev. Immunol, vol.30, pp.1-22, 2012. ,
ALK inhibitors in non-small cell lung cancer : the latest evidence and developments, Ther Adv Med Oncol, vol.8, pp.32-47, 2016. ,
Regulation and Function of the PD-L1 Checkpoint, Immunity, vol.48, pp.434-452, 2018. ,
PD-1/PD-L1 inhibitors, Curr Opin Pharmacol, vol.23, pp.32-38, 2015. ,
Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer, DNA Res, vol.24, p.160, 2017. ,
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer, Clin. Cancer Res, vol.19, pp.1021-1034, 2013. ,
TIminer : NGS data mining pipeline for cancer immunology and immunotherapy, Bioinformatics, vol.33, pp.3140-3141, 2017. ,
Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Res, vol.75, pp.2139-2145, 2015. ,
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers, J. Clin. Oncol, vol.36, pp.1685-1694, 2018. ,
Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy, Eur. J. Cancer, vol.55, pp.7-14, 2016. ,
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med, vol.366, pp.2443-2454, 2012. ,
Exposure to environmental tobacco smoke and risk of lung cancer : the epidemiological evidence, Eur. Respir. J, vol.7, pp.1877-1888, 1994. ,
Professional drivers and lung cancer : a systematic review and meta-analysis, Occup Environ Med, vol.69, pp.831-836, 2012. ,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-571, 2014. ,
Introducing whole-genome sequencing into routine cancer care : the, Genomics England, vol.100 ,
, Genomes Project. Ann. Oncol, vol.29, pp.784-787, 2018.
Evaluation of Oxford Nanopore's MinION Sequencing Device for Microbial Whole, Genome Sequencing Applications. Sci Rep, vol.8, p.10931, 2018. ,
From FastQ data to high confidence variant calls : the Genome Analysis Toolkit best practices pipeline, Curr Protoc Bioinformatics, vol.43, pp.1-33, 2013. ,
5-Fluorouracil selectively kills tumorassociated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity, Cancer Res, vol.70, pp.3052-3061, 2010. ,
Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System, Journal of Clinical Oncology, vol.34, pp.3034-3034, 2016. ,
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment, Int. Immunopharmacol, vol.46, pp.210-219, 2017. ,
APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer, Oncogene, vol.37, pp.3924-3936, 2018. ,
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors, Front Immunol, vol.9, p.1310, 2018. ,
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab, Clin. Cancer Res, vol.22, p.161, 2016. ,
A Bayesian approach to assess interaction between known risk factors : the risk of lung cancer from exposure to asbestos and smoking, Stat Methods Med Res, vol.17, pp.171-189, 2008. ,
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer, Cell, vol.173, pp.1770-1782, 2018. ,
Circulating and Tumor Myeloidderived Suppressor Cells in Resectable Non-Small Cell Lung Cancer, Am. J. Respir. Crit. Care Med, vol.198, pp.777-787, 2018. ,
Targeting neoantigens to augment antitumour immunity, Nat. Rev. Cancer, vol.17, pp.209-222, 2017. ,
Autophagy, Inflammation, and Immunity : A Troika Governing Cancer and Its Treatment, Cell, vol.166, pp.288-298, 2016. ,
Cancer despite immunosurveillance : immunoselection and immunosubversion, Nat. Rev. Immunol, vol.6, pp.715-727, 2006. ,
Inhibitory B7-family molecules in the tumour microenvironment, Nat. Rev. Immunol, vol.8, pp.467-477, 2008. ,
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer, World J Clin Oncol, vol.10, pp.75-85, 2019. ,
Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors, Oncoimmunology, vol.8, p.1568812, 2019. ,
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT : a promising new combination, J Immunother Cancer, vol.7, p.160, 2019. ,
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients, Oncoimmunology, vol.8, p.1564505, 2019. ,
Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients, Clin. Cancer Res, vol.25, pp.957-966, 2019. ,
Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma, Oncotarget, vol.9, pp.25617-25629, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01821601
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy, Br. J. Cancer, vol.119, pp.950-960, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01980112
Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU) : a single-arm phase 2 study, Oncoimmunology, vol.7, p.1474319, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01880140
EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma, World J Gastrointest Oncol, vol.10, pp.103-107, 2018. ,
IRF8-dependent molecular complexes control the Th9 transcriptional program, Nat Commun, vol.8, p.2085, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01682219
Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer, Oncoimmunology, vol.6, p.1339856, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01694057
Antibiotic Use Does Not Appear to Influence Response to Nivolumab, Anticancer Res, vol.37, p.163, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01545832
Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein, World J. Gastroenterol, vol.22, pp.10680-10686, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01452654
, Communications affichées
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT : a promising combination. Abstract PV-0537, Présenté au 38ème congrès annuel de l'ESTRO, 2019. ,
Angiotensin-Converting Enzyme Inhibitor Is Associated with Decreased Survival in NSCLC Patients Treated with PD-1 Checkpoint Blockers, Abstract #2389, 2019. ,
Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PD1/PDL1 Immune Checkpoint Inhibitors. Abstract #2333, 2019. ,
An Interactive Interface for Prediction of Anti-PD-1 Efficacy in Lung Cancer Patients. Abstract #2460, 2019. ,
CD8 and PD-L1 determination in lung tumor tissue as prognostic biomarker and a predictive marjer of anti-PD-1 efficacy. Abstract #3021, 2018. ,
, La voie TIM-3/Galectine-9 et les MDSC monocytaires (mMDSC) sont impliquées dans la résistance au Nivolumab dans les cancers bronchiques de stade III/IV. Abstract SP11-44, 2018.
Exome Analysis to Reveal Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Abstract #9044, Présenté au congrès annuel de l, 2018. ,
Exome Analysis to Reveal Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Abstract P2, Présenté au congrès WIN Symposium, vol.22, 2018. ,
Exome Analysis to Reveal Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients, Présenté au Forum des Jeunes Chercheurs, vol.54, 2018. ,
Response to firstline chemotherapy regimen to predict efficacy of nivolumab in lung cancer. Abstract #3026, Présenté au congrès annuel de l, 2017. ,